Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Merck's annualized net income for the quarter that ended in Jun. 2023 was $-23,900 Mil. Merck's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $1,801 Mil. Therefore, Merck's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was -1,327.41%.
The historical rank and industry rank for Merck's Return-on-Tangible-Equity or its related term are showing as below:
MRK'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 34.59 Med: 73.78 Max: 162.34
Current: 162.34
During the past 13 years, Merck's highest Return-on-Tangible-Equity was 162.34%. The lowest was 34.59%. And the median was 73.78%.
MRK's Return-on-Tangible-Equity is ranked better than 94.86% of 972
companies
in the Drug Manufacturers industry
Industry Median: 6.20
vs MRK: 162.34
Merck Return-on-Tangible-Equity Historical Data
The historical data trend for Merck's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Merck Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Return-on-Tangible-Equity
Negative Tangible Equity
Negative Tangible Equity
Negative Tangible Equity
Negative Tangible Equity
Negative Tangible Equity
Merck Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Return-on-Tangible-Equity
Negative Tangible Equity
1,776.08
374.32
219.41
-1,327.41
Competitive Comparison
For the Drug Manufacturers - General subindustry, Merck's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck Return-on-Tangible-Equity Distribution
For the Drug Manufacturers industry and Healthcare sector, Merck's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Merck's Return-on-Tangible-Equity falls in comparison to its industry or sector. The grey bar indicates the Return-on-Tangible-Equity's extreme value range as defined by GuruFocus.
Merck Return-on-Tangible-Equity Calculation
Merck's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Merck Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Merck's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.39(0.37%) Volume: 4,965,330 11:09PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
MRK has been successfully added to your 
